Clinical Trials Logo

Advanced Ovarian Cancer clinical trials

View clinical trials related to Advanced Ovarian Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06055348 Not yet recruiting - Clinical trials for Advanced Ovarian Cancer

SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer

Start date: October 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A phase Ib/II clinical study on the safety, pharmacokinetic characteristics, and preliminary efficacy of SC0191 combination chemotherapy in patients with advanced ovarian cancer.

NCT ID: NCT05924776 Not yet recruiting - Clinical trials for Advanced Ovarian Cancer

Plasmodium Immunotherapy for Advanced Ovarian Cancer

Start date: April 20, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the safety and effectiveness of Plasmodium immunotherapy in the treatment of advanced ovarian cancer. This study plans to enroll 30 patients with advanced ovarian cancer. Each patient is inoculated with Plasmodium vivax 1-5 × 10^6, observe the time when the parasite is detected in the peripheral blood of the subjects after the inoculation of Plasmodium, the change of the parasite density in the peripheral blood of the whole treatment cycle and the control effect of the drug on the parasite density, the main clinical symptoms and signs, laboratory test indicators, immunological test indicators and changes in the quality of life. To evaluate the safety and tolerance of the subjects to Plasmodium immunotherapy, as well as the changes of tumor related indicators and immunological indicators.

NCT ID: NCT05794659 Not yet recruiting - Clinical trials for Advanced Ovarian Cancer

Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer

Cornerstone4
Start date: November 15, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this phase 2 study is to assess the efficacy and safety for adjuvant therapeutic cancer vaccine AST-201 (pUMVC3-hIGFBP-2) in patients with newly diagnosed homologous-recombination proficient(HRP) advanced ovarian cancer (Stage III) after debulking surgery. Patients will receive AST-201 with rhuGM-CSF(Colony Stimulating Factor) or placebo with rhuGM-CSF in combination with standard adjuvant chemotherapy(Paclitaxel/Carboplatin).

NCT ID: NCT03611179 Not yet recruiting - Clinical trials for Advanced Ovarian Cancer

Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer

Start date: September 1, 2018
Phase: Phase 2
Study type: Interventional

Our study aims at assessment of response, survival and toxicity of frontline treatment with chemotherapy and Bevacizumab in patients having advanced epithelial ovarian cancer.